Linked Life Data

19131038

Source:http://linkedlifedata.com/resource/pubmed/id/19131038

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2009-1-9
pubmed:abstractText
Levodopa is the most appropriate drug in theory for supplementing dopamine deficiency in the brain of Parkinson's disease (PD) patients. In consideration of the pharmacological properties of levodopa, measurement of 3,4-dihydroxyphenylalanine (DOPA) plasma concentration is significant and important in daily medical care. Akinesia of advanced PD patients comprises a combination of two distinct symptoms, hypokinesia and bradykinesia. It is probable that hypokinesia in PD does not originate from failure of neural pathways from the substantia nigra to motor striatum but is associated with dysfunction of the limbic striatum. Herein the pathophysiologic condition of the limbic striatum in PD patients is discussed and reasons suggested why drug efficacy of dopamine replenishment in this system is meager.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1353-8020
pubmed:author
pubmed:issnType
Print
pubmed:volume
15 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S25-30
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
pubmed:affiliation
Department of Neurology, Tokyo Metropolitan Health and Medical Treatment Corp., Ebara Hospital, 4-5-10 Higashiyukigaya, Ota, Tokyo, Japan. myokochi-e@ebara-hp.ota.tokyo.jp
pubmed:publicationType
Journal Article, Review